Clinical effectiveness in first-episode patients

R I Ohlsen, M S O'Toole, R G Purvis, J T R Walters, T M Taylor, H M Jones, L S Pilowsky

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)


Managing patients with first-episode schizophrenia is a challenging task for psychiatrists. Early diagnosis and effective intervention are vital to achieving long-term positive clinical outcomes among first-episode patients. Although these patients are the most responsive to treatment, they are also more susceptible to adverse events. The efficacy and improved tolerability associated with the newer atypical antipsychotics means that these drugs can be used successfully in the treatment and long-term management of schizophrenia from the onset of illness. However, as well as managing the symptoms of the disease, pharmacological treatments need to meet the broader requirements of clinical effectiveness that encompass all of the outcome domains associated with schizophrenia. This article will discuss available data on atypical antipsychotics in first-episode patients and present the primary results from the FIRST (Southwark first-onset psychosis) study, which examined the use of quetiapine for the first-line management of schizophrenia as part of a specialist episode psychosis service. (C) 2004 Elsevier B.V. and ECNP. All rights reserved.
Original languageEnglish
Pages (from-to)S445 - S451
JournalEuropean Neuropsychopharmacology
Issue numberSUPPL. 4
Publication statusPublished - Nov 2004


Dive into the research topics of 'Clinical effectiveness in first-episode patients'. Together they form a unique fingerprint.

Cite this